{"id":"comparator-ceftriaxone-metronidazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypersensitivity reactions (cephalosporin)"},{"rate":null,"effect":"Metallic taste (metronidazole)"},{"rate":null,"effect":"Pseudomembranous colitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftriaxone binds to penicillin-binding proteins and inhibits cross-linking of peptidoglycan in the bacterial cell wall, leading to cell lysis. Metronidazole is reduced by anaerobic bacteria to form reactive intermediates that damage DNA and proteins. Together, they provide broad-spectrum coverage against aerobic gram-negative, gram-positive, and anaerobic bacteria.","oneSentence":"This is a fixed-dose combination of two antibiotics: ceftriaxone (a third-generation cephalosporin) inhibits bacterial cell wall synthesis, while metronidazole is a nitroimidazole that disrupts anaerobic bacterial DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:49.382Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intra-abdominal infections (polymicrobial)"},{"name":"Gynecological infections"},{"name":"Anaerobic bacterial infections"}]},"trialDetails":[{"nctId":"NCT01254344","phase":"PHASE3","title":"Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-12","conditions":"Infection, Surgical Site Infection","enrollment":599},{"nctId":"NCT00481702","phase":"PHASE3","title":"A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-12","conditions":"Intra-abdominal Infection","enrollment":300},{"nctId":"NCT00157898","phase":"PHASE4","title":"A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-01","conditions":"Complicated Intra-abdominal Infection","enrollment":134}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Comparator: ceftriaxone + metronidazole","genericName":"Comparator: ceftriaxone + metronidazole","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of two antibiotics: ceftriaxone (a third-generation cephalosporin) inhibits bacterial cell wall synthesis, while metronidazole is a nitroimidazole that disrupts anaerobic bacterial DNA. Used for Intra-abdominal infections (polymicrobial), Gynecological infections, Anaerobic bacterial infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}